Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection (PROTECT)

Do you live with someone who has COVID-19? Are you willing to take an investigational drug or placebo?

Sponsored by Johns Hopkins University

If you answered YES to both these questions, you may be eligible for a paid research study to test a drug for prevention of coronavirus infection.

The PROTECT study is recruiting household contacts of people who have been diagnosed with SARS-CoV-2 infection for a research study of use of an investigational drug Interferon Lambda, also called “Lambda”, in the prevention of COVID-19 illness.


Coronavirus disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. The virus that causes COVID-19 is a novel coronavirus that was first identified during an investigation into an outbreak in Wuhan, China.

How is this study designed?

Study type: Interventional (Clinical Trial) Estimated Enrollment: 164 participants Actual Study Start Date: May 29, 2020 Estimated Study Completion Date: December 2021

Who is this study for?

Persons who are aged 18-80 who have a household member who has been diagnosed with COVID-19 might be eligible.

What should I expect?

Compensation: Up to $50 as a gift card if all visits are completed

Duration of participation: 2 days of dosing, 12 weeks in total including follow-up

Connect with the study team

Thank you for your interest in advancing COVID-19 treatments.

Please fill out this contact form to be connected to a member of the study team. The following information that you enter will only be authorized to be shared with the research team conducting this specific study.

If you have any difficulties or questions, please contact our support specialists at [email protected]

Have a question?

For general questions about COVID-19 clinical trials, please email [email protected] For study specific inquiries, submit the interest form and you’ll be connected to the study team.